Mal-Val-Lys-PAB-CBI-PBD dimer 

Mal-Val-Lys-PAB-CBI-PBD dimer is a Drug-Linker Conjugates for ADC. Mal-Val-Lys-PAB-CBI-PBD dimer consists of the ADC Cytotoxin CBI-PBD dimer and a linker Mal-Val-Lys-PAB. Mal-Val-Lys-PAB-CBI-PBD dimer exhibits alkylating activity at A-T-rich DNA minor groove adenine residues, disrupting DNA integrity. Mal-Val-Lys-PAB-CBI-PBD dimer induces cancer cell growth inhibition and cellular death. Mal-Val-Lys-PAB-CBI-PBD dimer can be used for the research of cancer^[1].

Mal-Val-Lys-PAB-CBI-PBD dimer (Compound CBI-PBD dimer- linker (B)) can be used to synthesize HER2-targeting and CD22-targeting ADCs mediates antigen-dependent growth inhibition and cell death in HER2-positive and CD22-positive cancer cells in vitro^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1289.90

C₆₇H₈₅ClN₁₀O₁₄

1661824-39-0

O=C1C=CC(N1CCCCCC(N[C@H](C(N[C@@H](CCCCN)C(NC(C=C2)=CC=C2COC(N(C3=CC(OCCCCCC(N(C4)C(C=C(C5=CC=CC=C56)OC(N7CCN(C)CC7)=O)=C6[C@@H]4CCl)=O)=C(OC)C=C83)C(O)[C@@]9(CCCN9C8=O)[H])=O)=O)=O)C(C)C)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Yao HP, et al. Duocarmycin-based antibody-drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress. Drug Discov Today. 2021;26(8):1857-1874.  [Content Brief]